Rakuten Medical Pipeline
Rakuten Medical will continue advancing its research pipeline to provide innovative cancer therapies as quickly as possible. Currently, Rakuten Medical is conducting a global Phase 3 multi-center clinical trial with ASP-1929 in patients with recurrent head and neck squamous cell carcinoma. Moreover, early phase clinical trials investigating ASP-1929 in combination with anti-PD1, in multiple tumor types, are currently planned or underway (refer to www.ClinicalTrials.gov). In addition, Rakuten Medical is conducting additional early-stage research for investigative molecules such as RM-1995. More details on our full development pipeline can be found below:
DISCLAIMER: Outside of Japan, ASP-1929 photoimmunotherapy is investigational. ASP-1929 received the marketing approval in Japan from the Ministry of Health, Labour and Welfare in September 2020 and commercialized in January 2021.
a In collaboration with Shimadzu & the National Cancer Institute of National Institute of Health. A window of opportunity study takes place in the period between a cancer diagnosis and the subsequent initiation of standard treatment, during which, the patient receives a non-standard drug or treatment of interest over a short period of time.ⅰ ⅱ
ⅰ Aroldi F, Lord SR. Window of opportunity clinical trial designs to study cancer metabolism. Br J Cancer. 2020;122(1):45-51. doi:10.1038/s41416-019-0621-4
ⅱ Schmitz S, Duhoux F, Machiels JP. Window of opportunity studies: Do they fulfil our expectations? Cancer Treat Rev. 2016 Feb;43:50-7. doi: 10.1016/j.ctrv.2015.12.005. Epub 2015 Dec 31. PMID: 26827692.
- HNSCC: Head and Neck Squamous Cell Carcinoma
- CSCC: Cutaneous Squamous Cell Carcinoma
Source: Company Materials; ClinicalTrials.gov, JAPIC
(1) Investigator-initiated trials
(2) Planned trials in 2022
As of April 8, 2022
This pipeline graphic presents a selection of RMI’s product candidates and is designed to demonstrate our commitment to patients in our quest to conquer cancer. RMI’s pipeline will change over time as products move through the development process, including, as applicable, progressing through clinical phases to licensure, engaging in partnerships, in-licensing and out-licensing, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, all due to the nature of the drug and device development processes. This description contains forward-looking statements that involve significant risks and uncertainties, and actual results may vary materially. Unless otherwise noted, RMI provides this information as of April 2022, and RMI expressly disclaims any duty to update any of the provided information or forward-looking statements contained in this table as a result of new information, future events, or otherwise.